FIELD: medicine.
SUBSTANCE: invention relates to a method for treating breast cancer, involving administering a neoadjuvant therapy to a patient with HER2-positive, operable, locally advanced or edematous-infiltrative breast cancer, involving simultaneous administration of a combination of T-DM1 and pertuzumab, wherein said combination is administered in the absence of chemotherapy; removal of said breast cancer by radical surgery; as well as administering to the patient adjuvant therapy comprising simultaneous administration of a combination of T-DM1 and pertuzumab, wherein said combination is administered in the absence of chemotherapy.
EFFECT: invention provides treating breast cancer in a patient with HER2-positive, operable, locally advanced or edematous-infiltrative breast cancer.
16 cl, 6 dwg, 5 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-HER2 ANTIBODY DRUGS FOR SUBCUTANEOUS INJECTION | 2018 |
|
RU2750821C2 |
| COMBINATIONS OF ANTIBODY DRUG CONJUGATES AND CHEMOTHERAPEUTIC COMPOUNDS AND METHODS FOR USING | 2009 |
|
RU2510272C2 |
| COMBINATIONS OF ANTI-HER2-ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC REMEDIES, AND APPLICATION METHODS | 2018 |
|
RU2781195C2 |
| COMBINATIONS OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS AND METHODS OF USE | 2013 |
|
RU2671489C2 |
| PROCESS FOR TREATMENT OF BREAST CANCER USING NERATINIB | 2014 |
|
RU2685715C2 |
| DUOCARMICIN ADC SHOWING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2689779C2 |
| TREATMENT REGIMEN FOR BREAST CANCER USING NERATINIB | 2019 |
|
RU2804713C2 |
| DUOCARMYCIN ADCs EXHIBITING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2769700C2 |
| TREATING SYD985 PATIENTS WITH T-DM1 REFRACTORY CANCER | 2016 |
|
RU2728101C2 |
| MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE-3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | 2013 |
|
RU2665949C2 |
